Group
RET targeting TKI
Group Profile
| Therapeutic Class | Targeted Therapy |
| Drug Class | Tyrosine Kinase Inhibitors (TKIs) |
| Mechanism of Action | RET inhibitor |
| Drugs in group | Pralsetinib· Selpercatinib |
Study design
RT–Drug Timing Window
Study design
RT–Drug Timing Window
Radiobiological rationale for RT–drug interaction
No direct radiosensitization data; theoretical reduction of RET-driven radioresistance only (Mulligan, New England Journal of Medicine, 2023; Duke et al., Clinical Cancer Research, 2023); though evidence is limited.
The data above refer to patients treated with RET targeting TKI as the sole drug class,
excluding any concurrent use of drugs from other groups.
Individual Drugs
Select a drug to view its individual evidence base (drug + SBRT, no other concurrent systemic drugs). Drugs without available data are shown greyed out.